Market turmoil and declining valuations in biotech are not deterring Third Rock Ventures from doing what it has done since 2007: raising funds of increasing size to back new biotechs that it incubates internally. Partner Abbie Celniker explained to Scrip that the venture capital firm’s long-term planning, and having long-term investors, makes it less susceptible to market conditions.
On 15 June, the Boston-based venture capital firm announced it has raised $1.1bn, its biggest fund to date and one...






